A major drug pricing proposal sponsored by Senate Democrats led by Al Franken (D-Minn.) could be best described as a mix of very interesting nonstarters with one very attractive incentive for the drug industry to come the table in the form of copay caps.
The drug industry has been trying for years to get substantial copay reform. In fact, at the 2009 PhRMA annual meeting in San Antonio, then-CEO of AstraZeneca PLC David Brennan (now on Alexion Pharmaceuticals Inc